WIA
BMRN icon

Wetzel Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wetzel Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-41
Closed -$3.58K – 215
2024
Q2 		$3.58K Hold
41
– – ﹤0.01% 640
2024
Q1 		$3.69K Hold
41
– – ﹤0.01% 729
2023
Q4 		$4K Buy
+41
New +$3.63K ﹤0.01% 718

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Wetzel Investment Advisors's BMRN Position: Q3 2024 in Review

Wetzel Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 41 shares — an estimated $3.58K sold.

Wetzel Investment Advisors first reported a position in BMRN in Q4 2023 and held it in 3 quarters. The position peaked at $4K in Q4 2023. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • Wetzel Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Wetzel Investment Advisors sold 41 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $3.58K.
  • Wetzel Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Wetzel Investment Advisors's BioMarin Pharmaceuticals position peaked at $4K in Q4 2023.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Wetzel Investment Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.